Paper Details

  1. Home
  2. Paper Details

Immunosuppressive drugs after simultaneous pancreas-kidney transplantation.

Author: , ClaesK, CoosemansW, EvenepoelP, KuypersD R J, MaesB, MalaiseJ, PirenneJ, SquiffletJ P, Van OphemD, VanrenterghemY

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Short-term induction therapy in combined kidney-pancreas transplantation is effective and well tolerated. Tacrolimus causes fewer pancreas graft losses and fewer drug discontinuations due to side effects. When MMF is combined with tacrolimus, dose reductions and discontinuations are common.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: We report the early and late secondary effects of tacrolimus or cyclosporine-microemulsion (ME), in combination with mycophenolate mofetil (MMF), and rATG. PATIENTS AND METHODS: One hundred three patients were randomly assigned to tacrolimus (initial oral dose 0.2 mg/kg) and 102 to cy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.transproceed.2005.05.022

データ提供：米国国立医学図書館（NLM）

Immunosuppressive Drugs After Simultaneous Pancreas-Kidney Transplantation: A Comparative Study of Tacrolimus and Cyclosporine

Pancreas-kidney transplantation, a complex surgical procedure, requires lifelong immunosuppressive therapy to prevent rejection of the transplanted organs. This study investigates the early and late secondary effects of two commonly used immunosuppressants, tacrolimus and cyclosporine, in combination with mycophenolate mofetil (MMF) and anti-thymocyte globulin (rATG), in patients undergoing simultaneous pancreas-kidney transplantation.

Tacrolimus Emerges as a Promising Immunosuppressant in Pancreas-Kidney Transplantation

The study found that tacrolimus was associated with fewer pancreas graft losses and fewer drug discontinuations due to side effects compared to cyclosporine. These findings suggest that tacrolimus may offer a more favorable immunosuppressive profile for patients undergoing simultaneous pancreas-kidney transplantation, contributing to better graft survival and reduced complications.

Navigating the Complexities of Immunosuppression in Transplantation

This research provides valuable insights into the long-term management of immunosuppression after pancreas-kidney transplantation. The study highlights the importance of carefully selecting immunosuppressive agents based on individual patient characteristics and the need for ongoing monitoring to adjust treatment regimens as needed. Like a desert traveler carefully navigating a changing landscape, healthcare providers must adapt their treatment strategies to ensure optimal outcomes for patients undergoing transplantation.

Dr. Camel's Conclusion

Pancreas-kidney transplantation, a complex journey requiring lifelong immunosuppression, presents unique challenges. This study explores the effects of two common immunosuppressants, tacrolimus and cyclosporine, revealing that tacrolimus may offer a more favorable profile. Just as a desert traveler carefully chooses their path, healthcare providers must make informed decisions about immunosuppressive therapy, ensuring the best possible outcomes for patients embarking on this life-altering journey.

Date :
  1. Date Completed 2006-01-24
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

16182827

DOI: Digital Object Identifier

10.1016/j.transproceed.2005.05.022

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.